Clinical trial
Open-label Randomized Control Trial to Assess the Efficacy and Safety of Dual Anticoagulants i.e. Rivaroxaban Plus Aspirin and Clopidogrel Plus Aspirin in Patients Suffering From an Acute Coronary Syndrome
NCT05573958 is registered in ClinicalTrials.gov with Sarmad Zahoor as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Open-label Randomized Control Trial to Assess the Efficacy and Safety of Dual Anticoagulants i.e. Rivaroxaban Plus Aspirin and Clopidogrel Plus Aspirin in Patients Suffering From an Acute Coronary Syndrome
- Lead sponsor
- Sarmad Zahoor
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- October 1, 2022
- Completion date
- July 31, 2023
- Enrollment
- 90 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.